Tejus A, Mathur A G, Pradhan Sapna, Malik Salma, Salmani Md Fadil
Classified Specialist (Pharmacology), Medical Officer, HQ IMTRAT, C/o 99 APO, India.
Brig Med, 1 Corps, India.
Med J Armed Forces India. 2022 Apr;78(2):125-130. doi: 10.1016/j.mjafi.2021.09.005. Epub 2021 Nov 24.
Influenza is a frequent cause of clinically significant human disease, with seasonal epidemics and occasional pandemics. Uncomplicated influenza in healthy individuals is managed symptomatically. Vaccination against influenza plays a vital role in the control of infection in humans. The currently available antivirals include adamantanes, neuraminidase inhibitors, and ribavirin. Baloxavir marboxil, the prodrug of baloxavir, is the latest addition to the family of anti-influenza drugs, and it received US-FDA approval on October 24, 2018. Baloxavir acts through a novel mechanism of inhibiting Cap-dependent endonuclease (CEN), the vital step in the transcription of viral RNA, and prevents further spread of the virus.
流感是临床上导致人类重大疾病的常见病因，会引发季节性流行以及偶尔的大流行。健康个体的单纯性流感采取对症治疗。流感疫苗接种在控制人类感染方面发挥着至关重要的作用。目前可用的抗病毒药物包括金刚烷类、神经氨酸酶抑制剂和利巴韦林。巴洛沙韦酯（巴洛沙韦的前体药物）是抗流感药物家族中的最新成员，于2018年10月24日获得美国食品药品监督管理局（US-FDA）批准。巴洛沙韦通过一种新型机制发挥作用，即抑制帽依赖性核酸内切酶（CEN），这是病毒RNA转录的关键步骤，从而阻止病毒进一步传播。
